- Home
- MTEX vs BCTX Comparison
MTEX vs BCTX Comparison
Compare MTEX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- BCTX
- Stock Information
- Founded
- MTEX 1993
- BCTX 2014
- Country
- MTEX United States
- BCTX Canada
- Employees
- MTEX N/A
- BCTX N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- BCTX Health Care
- Exchange
- MTEX Nasdaq
- BCTX Nasdaq
- Market Cap
- MTEX 20.0M
- BCTX 23.5M
- IPO Year
- MTEX 1999
- BCTX N/A
- Fundamental
- Price
- MTEX $7.86
- BCTX $0.80
- Analyst Decision
- MTEX
- BCTX Strong Buy
- Analyst Count
- MTEX 0
- BCTX 1
- Target Price
- MTEX N/A
- BCTX $32.00
- AVG Volume (30 Days)
- MTEX 21.1K
- BCTX 2.4M
- Earning Date
- MTEX 08-12-2025
- BCTX 06-16-2025
- Dividend Yield
- MTEX N/A
- BCTX N/A
- EPS Growth
- MTEX N/A
- BCTX N/A
- EPS
- MTEX N/A
- BCTX N/A
- Revenue
- MTEX $115,036,000.00
- BCTX N/A
- Revenue This Year
- MTEX N/A
- BCTX N/A
- Revenue Next Year
- MTEX N/A
- BCTX N/A
- P/E Ratio
- MTEX N/A
- BCTX N/A
- Revenue Growth
- MTEX N/A
- BCTX N/A
- 52 Week Low
- MTEX $7.00
- BCTX $0.69
- 52 Week High
- MTEX $16.49
- BCTX $29.40
- Technical
- Relative Strength Index (RSI)
- MTEX 35.35
- BCTX 14.49
- Support Level
- MTEX $8.10
- BCTX $0.79
- Resistance Level
- MTEX $8.50
- BCTX $3.00
- Average True Range (ATR)
- MTEX 0.56
- BCTX 0.22
- MACD
- MTEX -0.10
- BCTX -0.20
- Stochastic Oscillator
- MTEX 0.00
- BCTX 5.51
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.